Page Menu

Cancer Physiology Department Metrics

View the clinical trials, grants and publications from the Department of Cancer Physiology.

Clinical Trials
CLINICAL TRIAL 19989
Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
Condition: Gastrointestinal Tumor
Intervention: Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Xeloda (capecitabine); capecitabine (); gemcitabine ()

CLINICAL TRIAL 20832
A Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization in Patients with Localized Prostate Carcinoma and Obstructive Lower Urinary Tract Symptoms
Condition: Genitourinary
Intervention:

CLINICAL TRIAL 21063
A Randomized Phase II Study of Atezolizumab and Bevacizumab with Y-90 TARE in Patients with Unresectable Hepatocellular Carcinoma (HCC)
Condition: Gastrointestinal Tumor
Intervention: Atezolizumab (Tecentriq); Avastin (Bevacizumab); Bevacizumab (); Not Applicable (); Yttrium-90 ()

CLINICAL TRIAL 21082
SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment
Condition: Genitourinary
Intervention: 177Lu-PNT2002 (); Abiraterone acetate (); Enzalutamide (Xtandi); Zytiga (Abiraterone acetate)

Grants
  • Investigation of NRF2-Dependent Metabolic Liabilities
    Sponsor: Nat Institutes of Health
    PI:DeNicola, G.
  • Investigation of NRF2-Dependent Metabolic Liabilities
    Sponsor: Nat Institutes of Health
    PI:DeNicola, G.
  • Perturbing the Evolutionary Drivers of Targeted Therapy Resistance in NSCLC
    Sponsor: Amer Cancer Society
    PI:Marusyk, A.
  • Imaging Acidosis and Immune Therapy in PDAC
    Sponsor: Nat Institutes of Health
    PI (Contact):Gillies, R.,PI (MPI):Pilon-Thomas, S.
  • Therapeutic strategies for KEAP1/NRF2 mutant lung cancer
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:DeNicola, G.
  • Exploiting Ecology and Evolution to Prevent Therapy Resistance in EGFR-Driven Lung Cancer
    Sponsor: Nat Institutes of Health
    PI:Marusyk, A.
  • Impact of Stromal Architecture on the Response of Lung Cancers to Targeted Therapies
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Marusyk, A.,CO-PI:Basanta Gutierrez, D.
  • Metabolic basis of the NADPH-independent disulfide reductase system in mouse liver
    Sponsor: Nat Institutes of Health
    PI (MPI):DeNicola, G.
  • Defining the Role of Metabolic Heterogeneity in Melanoma Dissemination and Therapy Escape
    Sponsor: Nat Institutes of Health
    PI:Smalley, I.
  • Effects of novel glucagon-like peptide 1 receptor (GLP-1R) agonists on comorbidities in Alzheimer's disease with diabetes mellitus.
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:McDonald, P.
  • Pyridine Nucleotides: Missing Link between Aging and Lung Cancer
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:DeNicola, G.,CO-PI:Gomes, A.
  • Evolution of Evolability Under Targeted Therapies
    Sponsor: Moffitt Cancer Center
    PI:Marusyk, A.,CO-PI:Basanta Gutierrez, D.
  • Predicting Dose Maps Adaptive Sterotatic Radiotherapy of Breast Cancer Metastases of the Brain St of FL COE Pilot Project 2
    Sponsor: Moffitt Cancer Center
    PI:Raghunand, N.,CO-PI:Ahmed, K.
  • Conjugates for Detection of Breast Cancer Nodal Metastasis
    Sponsor: Moffitt Cancer Center
    PI:Morse, D.,CO-PI:Luca, V.
  • Engineering Bispecific Nanobodies for Detection of Breast Cancer Nodal Metastasis
    Sponsor: US Army
    PI:Morse, D.
  • Impact of extracellular glutathione catabolism on triple-negative breast cancer
    Sponsor: Nat Institutes of Health
    PI:DeNicola, G.
  • A High Content Screening Platform for High Throughput, High Content Imaging and Analysis
    Sponsor: Nat Institutes of Health
    PI (Contact):McDonald, P.
  • Defining and targeting the immune-suppressive metabolic microenvironment of leptomeningeal melanoma metastases
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Smalley, I.
  • Defining and targeting the immune-suppressive metabolic microenvironment of leptomeningeal melanoma metastases
    Sponsor: Nat Institutes of Health
    PI:Smalley, I.
  • Tumor-Stroma Metabolic Crosstalk in Melanoma Brain Metastases
    Sponsor: Moffitt Cancer Center
    PI:Smalley, I.,CO-PI:Chen, A.
  • "Developing spatial multi-omics approaches for the study of the tumor microenvironment"
    Sponsor: Moffitt Cancer Center
    PI:Smalley, I.
  • Tumor-stroma metabolic crosstalk in melanoma brain metastases
    Sponsor: Melanoma Research Alliance (MRA)
    PI:Smalley, I.
Publications
  • Ravichandran M, Hu J, Cai C, Ward NP, Venida A, Foakes C, Kuljanin M, Yang A, Hennessey CJ, Yang Y, Desousa BR, Rademaker G, Staes AAL, Cakir Z, Jain IH, Aguirre AJ, Mancias JD, Shen Y, DeNicola GM, Perera RM. Coordinated Transcriptional and Catabolic Programs Support Iron-Dependent Adaptation to RAS-MAPK Pathway Inhibition in Pancreatic Cancer. Cancer Discov. 2022 Sep.12(9):2198-2219. Pubmedid: 35771494. Pmcid: PMC9444964.
  • Remsing Rix LL, Sumi NJ, Hu Q, Desai B, Bryant AT, Li X, Welsh EA, Fang B, Kinose F, Kuenzi BM, Chen YA, Antonia SJ, Lovly CM, Koomen JM, Haura EB, Marusyk A, Rix U. IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells. Sci Signal. 2022 Aug.15(747):eabj5879. Pubmedid: 35973030.
  • Ward NP, DeNicola GM. Long-sought mediator of vitamin K recycling discovered. Nature. 2022 Aug.608(7924):673-674. Pubmedid: 35922487.
  • Jiang C, Ward NP, Prieto-Farigua N, Kang YP, Thalakola A, Teng M, DeNicola GM. A CRISPR screen identifies redox vulnerabilities for KEAP1/NRF2 mutant non-small cell lung cancer. Redox Biol. 2022 Aug.54:102358. Pubmedid: 35667246. Pmcid: PMC9168196.
  • Somarelli JA, DeGregori J, Gerlinger M, Heng HH, Marusyk A, Welch DR, Laukien FH. Questions to guide cancer evolution as a framework for furthering progress in cancer research and sustainable patient outcomes. Med Oncol. 2022 Jul.39(9):137. Pubmedid: 35781581. Pmcid: PMC9252949.
  • Farrokhian N, Maltas J, Dinh M, Durmaz A, Ellsworth P, Hitomi M, McClure E, Marusyk A, Kaznatcheev A, Scott JG. Measuring competitive exclusion in non-small cell lung cancer. Sci Adv. 2022 Jul.8(26):eabm7212. Pubmedid: 35776787.
  • Jiang Q, Sudalagunta P, Silva MC, Canevarolo RR, Zhao X, Ahmed KT, Alugubelli RR, DeAvila G, Tungesvik A, Perez L, Gatenby R, Gillies R, Baz R, Meads MB, Shain KH, Silva AS, Zhang W. CancerCellTracker: A Brightfield Time-lapse Microscopy Framework for Cancer Drug Sensitivity Estimation. Bioinformatics. 2022 Jun. Pubmedid: 35751591.
  • Abou DS, Zerkel P, Robben J, McLaughlin M, Hazlehurst T, Morse D, Wadas TJ, Pandya DN, Oyama R, Gaehle G, Nickels ML, Thorek DLJ. Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies. Cancer Biother Radiopharm. 2022 Jun.37(5):355-363. Pubmedid: 35695807.
  • Wang X, Li Y, Li Z, Lin S, Wang H, Sun J, Lan C, Wu L, Sun D, Huang C, Singh PK, Hempel N, Trebak M, DeNicola GM, Hao J, Yang S. Mitochondrial Calcium Uniporter Drives Metastasis and Confers a Targetable Cystine Dependency in Pancreatic Cancer. Cancer Res. 2022 Jun.82(12):2254-2268. Pubmedid: 35413105. Pmcid: PMC9203979.
  • Vander Velde R, Shaffer S, Marusyk A. Integrating mutational and nonmutational mechanisms of acquired therapy resistance within the Darwinian paradigm. Trends Cancer. 2022 Jun.8(6):456-466. Pubmedid: 35307314.
  • Maccioni P, Kaczanowska K, McDonald P, Colombo G. Development of Partial Tolerance to the Suppressing Effect of the Positive Allosteric Modulator of the GABAB Receptor, KK-92A, on Alcohol Self-Administration in Rats. Alcohol Alcohol. 2022 May. Pubmedid: 35589119.
  • Pillai S, Mahmud I, Mahar R, Griffith C, Langsen M, Nguyen J, Wojtkowiak JW, Swietach P, Gatenby RA, Bui MM, Merritt ME, McDonald P, Garrett TJ, Gillies RJ. Lipogenesis mediated by OGR1 regulates metabolic adaptation to acid stress in cancer cells via autophagy. Cell Rep. 2022 May.39(6):110796. Pubmedid: 35545051. Pmcid: PMC9137419.
  • Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, Nguyen T, Karreth FA, Koomen JM, Sarnaik AA, Zager JS, Khushalani NI, Tarhini AA, Sondak VK, Rodriguez PC, Messina JL, Chen YA, Smalley KSM. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. Clin Cancer Res. 2022 May.28(10):2131-2146. Pubmedid: 35247927. Pmcid: PMC9106889.
  • Li J, DeNicola GM, Ruffell B. Metabolism in tumor-associated macrophages. Int Rev Cell Mol Biol. 2022 Apr.367:65-100. Pubmedid: 35461660. Pmcid: PMC9094395.
  • Foo J, Basanta D, Rockne RC, Strelez C, Shah C, Ghaffarian K, Mumenthaler SM, Mitchell K, Lathia JD, Frankhouser D, Branciamore S, Kuo YH, Marcucci G, Vander Velde R, Marusyk A, Hang S, Hari K, Jolly MK, Hatzikirou H, Poels K, Spilker M, Shtylla B, Robertson-Tessi M, Anderson ARA. Roadmap on plasticity and epigenetics in cancer. Phys Biol. 2022 Apr.19(3). Pubmedid: 35078159. Pmcid: PMC9190291.
  • Ospina OE, Wilson CM, Soupir AC, Berglund A, Smalley I, Tsai KY, Fridley B. spatialGE: Quantification and visualization of the tumor microenvironment heterogeneity using spatial transcriptomics. Bioinformatics. 2022 Mar. Pubmedid: 35258565.
  • Sriramareddy SN, Faião-Flores F, Emmons MF, Saha B, Chellappan S, Wyatt C, Smalley I, Licht JD, Durante MA, Harbour JW, Smalley KSM. HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma. Cancer Gene Ther. 2022 Mar. Pubmedid: 35332245.
  • Law V, Chen Z, Vena F, Smalley I, Macaulay R, Evernden BR, Tran N, Pina Y, Puskas J, Caceres G, Bayle S, Johnson J, Liu JKC, Etame A, Vogelbaum M, Rodriguez P, Duckett D, Czerniecki B, Chen A, Smalley KSM, Forsyth PA. A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. Neurooncol. 2022 Feb. Pubmedid: 35213727.
  • Ge EJ, Bush AI, Casini A, Cobine PA, Cross JR, DeNicola GM, Dou QP, Franz KJ, Gohil VM, Gupta S, Kaler SG, Lutsenko S, Mittal V, Petris MJ, Polishchuk R, Ralle M, Schilsky ML, Tonks NK, Vahdat LT, Van Aelst L, Xi D, Yuan P, Brady DC, Chang CJ. Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer. 2022 Feb.22(2):102-113. Pubmedid: 34764459. Pmcid: PMC8810673.
  • Bailey T, Nieto A, McDonald P. Inhibition of the Monocarboxylate Transporter 1 (MCT1) Promotes 3T3-L1 Adipocyte Proliferation and Enhances Insulin Sensitivity. Int J Mol Sci. 2022 Feb.23(3). Pubmedid: 35163825. Pmcid: PMC8836706.
  • Youssef I, Poch M, Raghunand N, Pow-Sang J, Johnstone PAS. Analysis of MRI radiomic pelvimetry and correlation with margin status after robotic prostatectomy. Can J Urol. 2022 Feb.29(1):10976-10978. Pubmedid: 35150217.
  • Weinfurtner RJ, Raghunand N, Stringfield O, Abdalah M, Niell BL, Ataya D, Williams A, Mooney B, Rosa M, Lee MC, Khakpour N, Laronga C, Czerniecki B, Diaz R, Ahmed K, Washington I, Montejo M. MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity. Clin Breast Cancer. 2022 Feb.22(2):e214-e223. Pubmedid: 34384695.
  • Mecozzi N, Nenci A, Vera O, Bok I, Falzone A, DeNicola GM, Karreth FA. Genetic tools for the stable overexpression of circular RNAs. RNA Biol. 2022 Jan.19(1):353-363. Pubmedid: 35289721. Pmcid: PMC8928841.
  • Torrente L, DeNicola GM. Targeting NRF2 and Its Downstream Processes: Opportunities and Challenges. Annu Rev Pharmacol Toxicol. 2022 Jan.62:279-300. Pubmedid: 34499527.
  • Bayer P, Gatenby RA, McDonald PH, Duckett DR, Staňková K, Brown JS. Coordination games in cancer. PLoS One. 2022 Jan.17(1):e0261578. Pubmedid: 35061724. Pmcid: PMC8782377.
  • Mostofa A, Distler A, Meads MB, Sahakian E, Powers JJ, Achille A, Noyes D, Wright G, Fang B, Izumi V, Koomen J, Rampakrishnan R, Nguyen TP, De Avila G, Silva AS, Sudalagunta P, Canevarolo RR, Siqueira Silva MDC, Alugubelli RR, Dai HA, Kulkarni A, Dalton WS, Hampton OA, Welsh EA, Teer JK, Tungesvik A, Wright KL, Pinilla-Ibarz J, Sotomayor EM, Shain KH, Brayer J. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. JCI Insight. 2021 Dec.6(24). Pubmedid: 34793338. Pmcid: PMC8783683.
  • Pandey S, Snider AD, Moreno WA, Ravi H, Bilgin A, Raghunand N. Joint total variation-based reconstruction of multiparametric magnetic resonance images for mapping tissue types. Nmr Biomed. 2021 Dec.34(12):e4597. Pubmedid: 34390047.
  • Yoon SJ, DeNicola GM. IL1RAP Pulls a Double Shift in the Cysteine Factory. Cancer Discov. 2021 Nov.11(11):2679-2681. Pubmedid: 34725089.
  • DeNicola GM, Shackelford DB. Metabolic Phenotypes, Dependencies, and Adaptation in Lung Cancer. Cold Spring Harb Perspect Med. 2021 Nov.11(11). Pubmedid: 34127512. Pmcid: PMC8559540.
  • Zhou L, Zhang Y, Meads MB, Dai Y, Ning Y, Hu X, Li L, Sharma K, Nkwocha J, Parker R, Bui D, McCarter J, Kramer L, Purcell C, Sudalagunta P, Renatino Canevarolo R, Coelho Siqueira Silva MD, DeAvila G, Alugubelli RR, Siqueira Silva A, Kmieciak M, Ferreira-Gonzalez A, Shain KH, Grant S. IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB- and caspase-8-dependent mechanisms. Blood Adv. 2021 Oct.5(19):3776-3788. Pubmedid: 34464977. Pmcid: PMC8679669.
  • Tafreshi NK, Pandya DN, Tichacek CJ, Budzevich MM, Wang Z, Reff JN, Engelman RW, Boulware DC, Chiappori AA, Strosberg JR, Ji H, Wadas TJ, El-Haddad G, Morse DL. Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2021 Oct.48(11):3408-3421. Pubmedid: 33772332.
  • Maccioni P, Kaczanowska K, Lawrence H, Yun S, Bratzu J, Gessa GL, McDonald P, Colombo G. The Novel Positive Allosteric Modulator of the GABAB Receptor, KK-92A, Suppresses Alcohol Self-Administration and Cue-Induced Reinstatement of Alcohol Seeking in Rats. Front Cell Dev Biol. 2021 Oct.9:727576. Pubmedid: 34778249. Pmcid: PMC8585307.
  • Lin S, Li Y, Wang D, Huang C, Marino D, Bollt O, Wu C, Taylor MD, Li W, DeNicola GM, Hao J, Singh PK, Yang S. Fascin promotes lung cancer growth and metastasis by enhancing glycolysis and PFKFB3 expression. Cancer Lett. 2021 Oct.518:230-242. Pubmedid: 34303764. Pmcid: PMC8355190.